Frontlight ResearchEarly access
Active, not recruitingNo phase
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 112 people, planned
- Started
- 21 Sept 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ortho-k lenses
- 0.01% Atropine
- Record updated
- 18 August 2026
Who can take part
- Age
- 8 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Aged 8-15 years old
- Spherical equivalent refractions (SERs) -0.50 to -6.00 Dioptres (D) and astigmatism less than -1.5 D in both eyes, anisometropia less than 1.5 D
- Best corrected visual acuity (BCVA) equal to or better than 20/25 in both eyes
- Bilateral intra-ocular pressure < 21mmHg
- Normal binocular and stereoscopic visual function
- Participants and their guardians' understanding and acceptance of random allocation of grouping
Who cannot take part
- Previous use of myopia control without washout, including atropine, myopia control spectacles, myopia control contact lenses
- Ocular or systemic diseases which may affect vision or refractive error
- Manifest strabismus, except for intermittent tropia
- Other contraindications
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.
The 2 groups in the trial
- Ortho-k and 0.01% atropine sequential treatmentTreatment being tested
Participants will be treated with ortho-k lenses during the first year, and swiched to recieve 0.01% atropine twice a day in the second year.
Treatment: Ortho-k lenses and 0.01% Atropine
- Ortho-k continuous treatmentExisting treatment, for comparison
Participants will be treated with ortho-k lenses throughout, during the 2-year study period.
Treatment: Ortho-k lenses
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myopia Control Effect of Orthokeratology and 0.01% Atropine Sequential Treatment in Children and Adolescents: A Multicenter Randomized Controlled Trial
- Record updated
- 18 August 2026